FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002113121> ?p ?o ?g. }

• W2002113121 endingPage "e108035" @default.
• W2002113121 startingPage "e108035" @default.
• W2002113121 abstract "Sputum cultures are an important tool in monitoring the response to tuberculosis treatment, especially in multidrug-resistant tuberculosis. There has, however, been little study of the effect of treatment regimen composition on culture conversion. Well-designed clinical trials of new anti-tuberculosis drugs require this information to establish optimized background regimens for comparison. We conducted a retrospective cohort study to assess whether the use of an aggressive multidrug-resistant tuberculosis regimen was associated with more rapid sputum culture conversion. We conducted Cox proportional-hazards analyses to examine the relationship between receipt of an aggressive regimen for the 14 prior consecutive days and sputum culture conversion. Sputum culture conversion was achieved in 519 (87.7%) of the 592 patients studied. Among patients who had sputum culture conversion, the median time to conversion was 59 days (IQR: 31-92). In 480 patients (92.5% of those with conversion), conversion occurred within the first six months of treatment. Exposure to an aggressive regimen was independently associated with sputum culture conversion during the first six months of treatment (HR: 1.36; 95% CI: 1.10, 1.69). Infection with human immunodeficiency virus (HR 3.36; 95% CI: 1.47, 7.72) and receiving less exposure to tuberculosis treatment prior to the individualized multidrug-resistant tuberculosis regimen (HR: 1.58; 95% CI: 1.28, 1.95) were also independently positively associated with conversion. Tachycardia (HR: 0.77; 95% CI: 0.61, 0.98) and respiratory difficulty (HR: 0.78; 95% CI: 0.62, 0.97) were independently associated with a lower rate of conversion. This study is the first demonstrating that the composition of the multidrug-resistant tuberculosis treatment regimen influences the time to culture conversion. These results support the use of an aggressive regimen as the optimized background regimen in trials of new anti-TB drugs." @default.
• W2002113121 created "2016-06-24" @default.
• W2002113121 creator A5009507901 @default.
• W2002113121 creator A5019404179 @default.
• W2002113121 creator A5024339381 @default.
• W2002113121 creator A5024772438 @default.
• W2002113121 creator A5026613536 @default.
• W2002113121 creator A5027153983 @default.
• W2002113121 creator A5038559170 @default.
• W2002113121 creator A5048278752 @default.
• W2002113121 creator A5050520650 @default.
• W2002113121 creator A5051602286 @default.
• W2002113121 creator A5052396258 @default.
• W2002113121 creator A5080698414 @default.
• W2002113121 creator A5081538965 @default.
• W2002113121 creator A5082730150 @default.
• W2002113121 creator A5087376331 @default.
• W2002113121 date "2014-09-19" @default.
• W2002113121 modified "2023-10-17" @default.
• W2002113121 title "Time to Culture Conversion and Regimen Composition in Multidrug-Resistant Tuberculosis Treatment" @default.
• W2002113121 cites W1570622790 @default.
• W2002113121 cites W1966279006 @default.
• W2002113121 cites W1976113829 @default.
• W2002113121 cites W1984391752 @default.
• W2002113121 cites W1996794817 @default.
• W2002113121 cites W2008760177 @default.
• W2002113121 cites W2016436785 @default.
• W2002113121 cites W2052416660 @default.
• W2002113121 cites W2083509737 @default.
• W2002113121 cites W2098793988 @default.
• W2002113121 cites W2110181046 @default.
• W2002113121 cites W2110944556 @default.
• W2002113121 cites W2131365485 @default.
• W2002113121 cites W2136694704 @default.
• W2002113121 cites W2144362977 @default.
• W2002113121 cites W2153385258 @default.
• W2002113121 cites W2165192487 @default.
• W2002113121 cites W2171417449 @default.
• W2002113121 cites W2316156979 @default.
• W2002113121 cites W2323586564 @default.
• W2002113121 doi "https://doi.org/10.1371/journal.pone.0108035" @default.
• W2002113121 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4169600" @default.
• W2002113121 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25238411" @default.
• W2002113121 hasPublicationYear "2014" @default.
• W2002113121 type Work @default.
• W2002113121 sameAs 2002113121 @default.
• W2002113121 citedByCount "27" @default.
• W2002113121 countsByYear W20021131212015 @default.
• W2002113121 countsByYear W20021131212016 @default.
• W2002113121 countsByYear W20021131212017 @default.
• W2002113121 countsByYear W20021131212018 @default.
• W2002113121 countsByYear W20021131212019 @default.
• W2002113121 countsByYear W20021131212020 @default.
• W2002113121 countsByYear W20021131212021 @default.
• W2002113121 countsByYear W20021131212022 @default.
• W2002113121 countsByYear W20021131212023 @default.
• W2002113121 crossrefType "journal-article" @default.
• W2002113121 hasAuthorship W2002113121A5009507901 @default.
• W2002113121 hasAuthorship W2002113121A5019404179 @default.
• W2002113121 hasAuthorship W2002113121A5024339381 @default.
• W2002113121 hasAuthorship W2002113121A5024772438 @default.
• W2002113121 hasAuthorship W2002113121A5026613536 @default.
• W2002113121 hasAuthorship W2002113121A5027153983 @default.
• W2002113121 hasAuthorship W2002113121A5038559170 @default.
• W2002113121 hasAuthorship W2002113121A5048278752 @default.
• W2002113121 hasAuthorship W2002113121A5050520650 @default.
• W2002113121 hasAuthorship W2002113121A5051602286 @default.
• W2002113121 hasAuthorship W2002113121A5052396258 @default.
• W2002113121 hasAuthorship W2002113121A5080698414 @default.
• W2002113121 hasAuthorship W2002113121A5081538965 @default.
• W2002113121 hasAuthorship W2002113121A5082730150 @default.
• W2002113121 hasAuthorship W2002113121A5087376331 @default.
• W2002113121 hasBestOaLocation W20021131211 @default.
• W2002113121 hasConcept C126322002 @default.
• W2002113121 hasConcept C141071460 @default.
• W2002113121 hasConcept C142724271 @default.
• W2002113121 hasConcept C167135981 @default.
• W2002113121 hasConcept C2776301714 @default.
• W2002113121 hasConcept C2777025531 @default.
• W2002113121 hasConcept C2777768864 @default.
• W2002113121 hasConcept C2777975735 @default.
• W2002113121 hasConcept C2779912665 @default.
• W2002113121 hasConcept C2781069245 @default.
• W2002113121 hasConcept C2781413609 @default.
• W2002113121 hasConcept C71924100 @default.
• W2002113121 hasConceptScore W2002113121C126322002 @default.
• W2002113121 hasConceptScore W2002113121C141071460 @default.
• W2002113121 hasConceptScore W2002113121C142724271 @default.
• W2002113121 hasConceptScore W2002113121C167135981 @default.
• W2002113121 hasConceptScore W2002113121C2776301714 @default.
• W2002113121 hasConceptScore W2002113121C2777025531 @default.
• W2002113121 hasConceptScore W2002113121C2777768864 @default.
• W2002113121 hasConceptScore W2002113121C2777975735 @default.
• W2002113121 hasConceptScore W2002113121C2779912665 @default.
• W2002113121 hasConceptScore W2002113121C2781069245 @default.
• W2002113121 hasConceptScore W2002113121C2781413609 @default.
• W2002113121 hasConceptScore W2002113121C71924100 @default.
• W2002113121 hasIssue "9" @default.

• next